CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations

This uniquely integrated capability incorporates CordenPharma's extensive experience in large-scale peptide drug substance, sterile injectable fill-finish, and oral solid dosage manufacturing. With built-in redundancy through multiple drug substance sites across its global facility network, CordenPharma is well-positioned to ensure a secure and uninterrupted supply chain throughout the lifecycle of Viking Therapeutics' VK2735 drug candidate.

Dr. Michael Quirmbach, President & CEO of the CordenPharma Group, comments: "We are proud to support Viking Therapeutics with a strong end-to-end offering for their complex modalities, from peptide drug substance to drug product, for this innovative VK2735 drug candidate. Our global teams are excited to provide true integration of our expertise across the pharma supply chain to meet the increasing demand for GLP-1 peptide therapeutics and ultimately, improve patient outcomes."

About CordenPharma

CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization.

With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency).

The CordenPharma Group is comprised of 11 facilities across Europe and North America. In the 2024 financial year, the organization generated sales of €854 million and had over 3,000 employees. In 2022, CordenPharma was acquired by Astorg - a leading Pan-European private equity firm with deep expertise in the healthcare sector - to accelerate its development and further strengthen its leadership in the CDMO peptide space.

Please visit cordenpharma.com for more information I Follow CordenPharma on LinkedIn.

View original content:https://www.prnewswire.co.uk/news-releases/cordenpharma-and-viking-therapeutics-sign-long-term-strategic-partnership-for-integrated-supply-of-glp-1-peptides-injectables-and-oral-formulations-302397601.html